Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsten Fischer

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2017
Optimizing frontline therapy of CLL based on clinical and biological factorsKirsten Fischer, Michael Hallek
Blood|May 9, 2015
Targeted drugs in concert with chemo: opposites attractClemens-Martin Wendtner, Kirsten Fischer
Blood|December 23, 2021
TP53 mutations in CLL: does frequency matter?Othman Al-Sawaf, Kirsten Fischer
Current Protocols in Immunology|April 25, 2008
Listing, location, binding motifs, and expression of nonclassical class I and related genes and moleculesJames Forman, Kirsten Fischer Lindahl
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy in patients with Richter transformationKirsten Fischer, Othman Al-Sawaf
Current Opinion in Genetics & Development|June 3, 2004
Good copy, bad copy: choosing animal models for HLA-linked diseasesAttila Kumánovics, Kirsten Fischer Lindahl
Physical Review. E|January 21, 2026
Field theory for optimal signal propagation in residual networksKirsten Fischer, David Dahmen, Moritz Helias
Immunogenetics|March 21, 2002
Does the rat have an H2-D orthologue next to Bat1?Doris Lambracht-Washington, Kirsten Fischer Lindahl
The New England Journal of Medicine|June 12, 2014
Chemoimmunotherapy for chronic lymphocytic leukemia. Author replyValentin Goede, Kirsten Fischer, Michael Hallek
Immunogenetics|April 8, 2004
Active MHC class Ib genes in rat are pseudogenes in the mouseDoris Lambracht-Washington, Kirsten Fischer Lindahl
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Hematology. American Society of Hematology. Education Program|December 10, 2017
Optimizing frontline therapy of CLL based on clinical and biological factorsKirsten Fischer, Michael Hallek
Blood|May 9, 2015
Targeted drugs in concert with chemo: opposites attractClemens-Martin Wendtner, Kirsten Fischer
Blood|December 23, 2021
TP53 mutations in CLL: does frequency matter?Othman Al-Sawaf, Kirsten Fischer
Current Protocols in Immunology|April 25, 2008
Listing, location, binding motifs, and expression of nonclassical class I and related genes and moleculesJames Forman, Kirsten Fischer Lindahl
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy in patients with Richter transformationKirsten Fischer, Othman Al-Sawaf
Current Opinion in Genetics & Development|June 3, 2004
Good copy, bad copy: choosing animal models for HLA-linked diseasesAttila Kumánovics, Kirsten Fischer Lindahl
Physical Review. E|January 21, 2026
Field theory for optimal signal propagation in residual networksKirsten Fischer, David Dahmen, Moritz Helias
Immunogenetics|March 21, 2002
Does the rat have an H2-D orthologue next to Bat1?Doris Lambracht-Washington, Kirsten Fischer Lindahl
The New England Journal of Medicine|June 12, 2014
Chemoimmunotherapy for chronic lymphocytic leukemia. Author replyValentin Goede, Kirsten Fischer, Michael Hallek
Immunogenetics|April 8, 2004
Active MHC class Ib genes in rat are pseudogenes in the mouseDoris Lambracht-Washington, Kirsten Fischer Lindahl
Pageof 15